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ABSTRACT 
 
 
Trauma is the fifth leading cause of death in individuals between age 5 and 45 
years worldwide. It will become the second leading cause by 2020.
 
Significant blood 
loss can occur due to traumatic coagulopathy caused by trauma, called “Acute 
Traumatic Coagulopathy”. This has been scantily described in the literature. Hence 
this study is aimed to study the effect of trauma on different parameters of coagulation 
profile and markers of fibrinolysis. 60 trauma patients between age 20 and 60 years 
were included. The incidence of coagulopathy was found to be 34% and overall 
mortality rate was 10.3 %. Association of variables like Tissue hypoperfusion, 
Severity of Injury, etc. with coagulopathy was proved to be statistically significant    
(p < 0.05). Association of the abovesaid variables with mortality was also studied and 
some were found to be significant. Those which were significant in univariate analysis 
were taken for multiple logistic regression analysis. Patients presenting with an 
established coagulopathy were likely to have poor outcomes, and hence must be 
identified as soon as possible and treated aggressively. 
 
Key words: Trauma, coagulopathy, Coagulation profile, Tissue hypoperfusion, Base deficit, 
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INTRODUCTION 
 
Trauma is the fifth leading cause of death in individuals between age 5 and 
45 years worldwide. It will become the second leading cause by 2020.
1 
Significant 
blood loss can occur due to traumatic coagulopathy caused by trauma.
2-3 
This entity 
called “Acute Traumatic Coagulopathy” has been scantily described in the literature.  
Traumatic coagulopathy of acute onset has been elucidated as an acquired 
disorder of blood coagulation system that happens due to loss or diminished function 
of proteases enzymes of coagulation system and platelets.  Severe trauma may lead to 
immense bleeding with stimulation of coagulation factors. This further cause 
subsequent exhaustion of the coagulation factors.
4 
The residual procoagulant potential 
also gets weakened by the administration of colloids and crystalloids. Colloids can 
directly disturb fibrin polymerization.
5
  
The achievement of hemostasis can also be disturbed by many factors like 
hypothermia, increased fibrinolysis, acidosis, and alterations in the electrolyte values. 
Among all these factors, first three factors straight away affect fibrin polymerization 
and metabolism.
6-7
 There is only partial increase in synthesis of fibrinogen during 
blood loss. This increase cannot be reimbursed due to concurrently occurring 
increased fibrinogen breakdown.
8-9 
The incidence of traumatic coagulopathy was 71% as already been reported 
by previous studies
10 
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Studies which are done recently have concluded that approximately 25% of 
patients with trauma present to the hospital with a coagulopathy when they seek 
admission which affects their overall outcome.
4
 
Coagulopathy remains an independent predictor of death among various 
predictors like severity of injury and degree of shock and this has been already proven 
by previous studies.
11
  
The Prothrombin time is a test to assess the decreased levels of factor VII 
and hence it may be mildly prolonged in trauma. Isolated elevations of the 
Prothrombin time reveals factor VII deficiency alone and are not indicative of severe 
coagulation defects. Prolonged aPTT in trauma indicates multiple and severe defects. 
Increased aPTTs over 1.8 times than controls has been associated with bleeding in 
several studies.
12-13
 
Coagulopathy is not only constrained to mortality but also related with 
unfortunate clinical outcome like acute renal injury, increased blood transfusion and 
prolonged stay in hospitals.
14-15 
In view of this, the present study is planned to study the effect of trauma on 
coagulation profile. Thus the basic coagulation tests like Bleeding Time, Clotting 
Time, Platelet count, Prothrombin Time (PT), Activated Partial Thromboplastin 
Time (aPTT) and other parameters like Fibrin, Fibrin Degradation Products,            
D- Dimer as a marker of fibrinolysis have been included in the study. Base deficit is 
also included as a marker of tissue hypoperfusion. 
 18 
 
This study is also planned to study the outcome variables related to 
morbidity like length of stay either in ICU or in the general ward, complications like 
acute renal injury and mortality of the trauma patients and their association with the 
coagulation profile. 
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AIM AND OBJECTIVES 
 
AIM  
To study the effect of trauma on different parameters of coagulation profile 
and markers of fibrinolysis. 
OBJECTIVES 
 To find out the prevalence of coagulopathy in trauma patients and to study its 
association with severity of injury. 
 To study the relationship between tissue hypoperfusion and coagulopathy. 
 To study the association between blood transfusion and coagulation defects. 
 To determine the association between coagulopathy, tissue hypoperfusion, 
renal injury and clinical outcome variables like morbidity and mortality. 
 To predict the role of  PT, aPTT on mortality. 
 To find the association of severity of injury with tissue hypoperfusion, lactate 
level and renal injury. 
 To determine the association of Acute Renal Dysfunction and coagulopathy.  
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REVIEW OF LITERATURE 
 
NORMAL COAGULATION PROCESS 
Haemostasis 
Haemostasis can be defined as stoppage of bleeding. Whenever there is injury 
to the blood vessel, the first and immediate event is vasoconstriction. This slackens 
the flow of blood to the affected area. 
Stable closure of the vessel by constriction and contact stickiness occurs only 
in the capillaries; however the stoppage of bleeding ultimately is dependent upon two 
other processes. 
 (1) Platelet plug formation and 
 (2) Coagulation (clotting) of blood.  
The blood platelets circulating in blood are involved in both processes. 
 
Platelet Plug formation 
The participation of platelets in haemostasis requires their adhesion to a surface 
of the endothelium. Platelets have a tendency for adhering to surfaces, but they do not 
stick to the normal endothelial lining of the blood vessels. Whenever blood vessel is 
injured, the endothelium gets disrupted. This causes exposure of the collagen beneath 
the endothelium.  
Platelets stick to the collagen, by means of von Willebrand factor (vWF). 
This is a plasma protein which is stashed by endothelial cells and platelets. This factor 
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binds with collagen which gets exposed due to tissue injury. This complex (vWF with 
collagen) undergoes conformational change, and attains the ability to adhere with 
platelets; thus vWF forms a link between the injured vessel and the platelets. 
 Adhesion of platelets to endothelium stimulates the platelets to discharge the 
contents stored in their secretory vesicles. This includes a variety of chemicals like 
Adenosine diphosphate (ADP), Thromboxane A2 and Serotonin. These chemicals 
induce multiple changes in the platelets like change in metabolism, shape, and surface 
proteins. This process termed platelet activation. Some of these changes cause new 
platelets to stick on to the old platelets in circulation. This phenomenon is termed as 
platelet aggregation that in turn leads a platelet plug inside the vessel. 
Adhesion of the platelets rapidly induces them to synthesize Thromboxane A2 
from arachidonic acid which is a content of the plasma membrane of a platelet. 
Thromboxane A2 stimulates platelet aggregation and also helps the platelets to secrete 
the contents of their secretory-vesicle. This is depicted in Figure 1. 
 Fibrinogen, a plasma protein also shows a crucial part in the platelet 
aggregation produced by the factors described above. It forms a link between 
aggregating platelets. Platelet activation exposes the fibrinogen receptor situated on 
the platelet plasma membrane.  
The platelet plug can entirely seal trivial breaks in wall of blood vessel. Its 
effectiveness is further enhanced by another property of platelets known as 
contraction. Platelets contain a very high concentration of actin and myosin, which are 
activated to contract in aggregated platelets. This causes a compression and thereby 
strengthens the platelet plug. (When they occur in a test tube, this contraction and 
 22 
 
compression are termed as “clot retraction”) While the platelet plug is being built up, 
the severed vessel undergoes vasoconstriction, thereby decreasing the blood flow to 
the severed area. This step is mediated by Thromboxane A2 and by several factors 
secreted from the secretory vesicles of platelets. 
 
Figure 1 – Steps of Haemostasis 
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Once started, the platelet plug does not expand continuously, spreading away 
from the severed endothelium along intact endothelium in both directions. One 
important reason for this is the synthesis of prostacyclin (also termed prostaglandin 
I2, (PGI2)). This inhibits platelet aggregation. (Figure 2).  
Normal endothelium also releases a potent vasodilator called nitric oxide, 
which also inhibits adhesion, activation, and aggregation of platelets. 
 
 
  
Figure 2 –Platelet Plug formation 
 
Coagulation 
 The process by which blood gets converted into a solid gel like material is 
coagulation or clotting of blood. The main component of this clot is fibrin which is a 
protein polymer. 
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Coagulation supports and reinforces the formation of platelet plug and helps to 
strengthen the solidified blood. The contact of platelet plug with the endothelium 
initiates a locally occurring sequence, or “cascade” of activation of various chemicals. 
Plasma protein which is in inactive form, or “factor,” is activated to an enzyme 
which causes proteolysis during each step of coagulation. Thus formed enzyme, 
catalyses the generation of the next enzyme in the sequence.  
The Prothrombin is converted to thrombin which acts as an enzyme. 
Thrombin catalyses the conversion of fibrinogen to fibrin.  
 Thus formed fibrin is a slack meshwork of interweaving strands. This is 
quickly become stable and fortified by cross-linkages formed by covalent bonds. This 
cross – linkage is catalysed by fibrin stabilising factor (Factor XIII) . This factor XIII 
is activated to factor XIIIa by thrombin.  Figure 3 depicts the formation of fibrin clot. 
 
 
  
Figure 3 : Formation of fibrin clot 
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In the process of clotting, many red blood cells and other cells like WBC, 
platelets etc. are entrapped in the meshwork of fibrin, but the crucial element of blood 
clot is fibrin. Thus blood coagulation may take place in the absence of any of the 
cellular components mentioned above except platelets. 
 
 The activation of platelets exposes a specific receptor that binds with several 
clotting factors. This makes the reactions to take place. The activated platelets also 
release platelet factor (PF) which functions as a cofactor in various steps. Calcium 
present in the plasma is required at various steps involved in coagulation process. 
 
Coagulation cascade 
 It consists of two seemingly parallel pathways that merge at the step before the 
prothrombin thrombin reaction. Under physiological conditions, however, the two 
pathways are not parallel but are actually brought into play sequentially, the link 
between them being thrombin.  
The pathways are  
(1)  Intrinsic pathway (everything necessary for it is within the blood vessel)  
(2) Extrinsic pathway (blood comes in contact with extrinsic environment  
     (i.e) tissue fluid, glass etc.) 
Intrinsic pathway  
The first factor in the intrinsic pathway is called factor XII.  When it contacts 
certain types of surfaces, including the collagen fibres underlying damaged 
endothelium, it becomes activated. The activation is a complex process that requires 
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the participation of several other plasma proteins like Prekallikerin, High Molecular 
weight Kininogen which are shown in Figure 4.  
Factor XIIa then catalyses the formation of factor XIa. This activates factor IX 
to factor IXa. This last factor IXa helps in the activation of factor X to factor Xa. 
Factor Xa acts as an enzyme in the conversion of prothrombin to thrombin. Another 
plasma protein—factor VIIIa—serves as a cofactor in the activation of factor X. 16 
 
 
Figure 4 : Intrinsic Pathway of coagulation
17
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Extrinsic pathway  
This pathway commences with tissue factor, which is found on the outer 
surface of cell membrane of fibroblasts and other cells in the blood vessel wall 
beneath the endothelial layer.  
 
 
Figure 5 : Extrinsic pathway of coagulation
17
 
 
Blood is exposed to these sub endothelial cells when vessel is damaged, and 
tissue factor on these cells then binds with factor VII. Thus factor VII is activated to 
factor VIIa. The complex of tissue factor and factor VIIa on the plasma membrane of 
the tissue cell then catalyses the activation of factor X. In addition, it catalyses factor 
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IX activation, which can then help activate even more factor X by plugging into the 
intrinsic pathway.( Figure 5) 
In summary, theoretically clotting can be initiated either by the generation of 
the tissue factor or by factor XII activation. The two paths become one at the point of 
activation of factor Xa, which further acts as a catalyst in the transformation of 
prothrombin to thrombin. Thrombin aids in fibrin formation. 
Thrombin also contributes to the activation of:  
(1) factors XI and VIII in the intrinsic pathway; and  
(2) factor V, with factor Va then serving as a cofactor for factor Xa.  
Thrombin also activates platelets. As stated earlier, under physiological 
conditions; the two pathways just described actually are brought into play 
sequentially.
16 
 (1)The extrinsic pathway is the traditional and major way of commencing coagulation 
in our body, and the intrinsic pathway plays minute role (in contrast to its 
initiation of clotting in wetable surfaces or, within the body in several unusual 
situations). Accordingly, thrombin is primarily generated only by the extrinsic 
pathway. The amount of thrombin is too small, however, to produce adequate and 
sustained coagulation.  
(2) It is great enough, though, to initiate thrombin’s positive-feedback effects on the 
intrinsic pathway—activation of factors XI and VIII and of platelets. 
(3) Thus the intrinsic pathway gets activated independently of Hageman factor (factor 
XII), and this pathway then generates the large amounts of thrombin required for 
adequate coagulation. In essence, thrombin eliminates the need for factor XII. 
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Moreover, thrombin not only recruits the intrinsic pathway but facilitates the 
prothrombin-thrombin step itself by activating factor V and platelets. The name of 
the clotting factors is given in Figure 6. 
 
 
Figure 6: Clotting Factors 
 
Finally it should be noted that the liver plays several important indirect roles 
in clotting (Figure 7), and persons with liver disease frequently have serious bleeding 
problems. First, the liver is the site of production for various clotting factors. Second, 
the bile salts which are essential for normal intestinal absorption of the lipid-soluble 
substance vitamin K are produced from liver. 
16
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Vitamin K is vital for mammals and for organisms that prepare food by 
photosynthesis. Plants are a dietary source of vitamin K for humans. In human beings, 
vitamin K is cofactor which is required for the γ-carboxylation of numerous elements 
involved in coagulation like Factor II, VII, IX, X and anticoagulant proteins.    
(Figure-8) This helps in proper of clotting factors, Ca
2+
, and membrane phospholipids 
and modulator proteins. 
18
 
 
Figure 7 – Vitamin K synthesis16 
 
 Vitamin K1, or phylloquinone (phytonadione) found in plants. It is the only 
natural vitamin K available for therapeutic use. Gram-positive bacteria synthesis 
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Vitamin K2 (the menaquinones). In our body intestinal flora are the major source of 
vitamin K. 
 
Figure 8 – Role of Vitamin K in the synthesis of Prothrombin 
 
In normal animals and humans, phylloquinone and menaquinones are virtually 
devoid of pharmacodynamic activity. However, in subjects deficient in vitamin K, the 
vitamin performs its normal physiological functions like γ-carboxylation.18 
 
FIBRINOLYTIC SYSTEM 
Our body has mechanisms for limiting clot formation, itself, and for dissolving 
a clot after it has formed. 
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Factors that oppose clot formation 
There are mainly three different mechanisms that oppose clot formation. 
Defects in any of these natural anticoagulant mechanisms are associated with 
abnormally high risk of clotting (hypercoagulability). 
 The first anticoagulant mechanism acts during the initiation phase of clotting 
and utilizes the plasma protein secreted by the endothelial cells called tissue factor 
pathway inhibitor (TFPI). This element fixes to tissue factor which get complexed 
with factor VIIa . Thus it inhibits the capability of these complexes to generate factor 
Xa. This anticoagulant mechanism is the reason that the extrinsic pathway by itself 
can generate only small amounts of thrombin. 
 The second anticoagulant mechanism is by thrombomodulin which is 
triggered by thrombin. Thrombin binds with thrombomodulin which is located in the 
endothelium as a surface receptor. 
 
Figure 9 – Factors that oppose clot formation  
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This binding abolishes the entire clot generating effects of thrombin and 
thrombin – thrombomodulin complex binds to a plasma protein called protein C. This 
activates protein C. This also needs the existence of co-factor called Protein S. This 
activated protein C then causes proteolysis of factors VIIIa and Va. This is explained 
by figure 9. 
A third naturally occurring mechanism that opposes the clot formation is by a 
plasma protein called antithrombin III. This antithrombin III binds with thrombin 
and inactivates it and inhibits the clot formation. 
To do so, circulating antithrombin III must itself be activated, and this occurs 
when it binds to heparin, a substance that is present on the surface of endothelial 
cells.  
 
Fibrinolysis 
TFPI, protein C, and antithrombin III are some of the factors that oppose clot 
formation and limit the size of the clot. The fibrinolytic system dissolves a clot after it 
is formed.  
It constitutes a proenzyme named as plasminogen which is present in the 
plasma. Plasminogen is activated to plasmin by protein plasminogen activators. 
Once plasmin is formed, it digests fibrin, thus promoting clot lysis. There are many 
types of plasminogen activators and numerous inhibitors (PAI-1 , PAI-2 etc.) of these 
plasminogen activators. One best example is the particular plasminogen activator 
known as tissue plasminogen activator (t-PA).
16 
 34 
 
Endothelial cells secrete this t-PA. During the mechanism of clot formation, 
both plasminogen and t-PA bind to fibrin and become integrated all through the clot. 
The binding of t-PA to fibrin is essential because t-PA is an enzyme which is very 
weak in the absence of fibrin.
 
 
 
      
Figure 10 – Fibrinolytic system 18 
 
 The presence of fibrin greatly surges the capacity of t-PA to convert the 
plasminogen to plasmin. (Figure - 10). Thus, fibrin is a key initiator of the fibrinolytic 
process that leads to its own dissolution. The secretion of t-PA is the last of the 
various anticlotting functions exerted by endothelial cells.
16 
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LABORATORY PARAMETERS  
o  COAGULATION PROFILE 
Bleeding Time 
Standard incision should be made on the flexor aspect of the forearm. Bleeding 
time is a measure of time till the incised wound bleeds. Cessation of bleeding is 
dependent on a sufficient number of platelets, the its adhesion via adhesion molecules 
such as vWF and fibrinogen.
19
 However, this test do not distinguish between defects 
in the vessel wall, thrombocytopenia, and platelet dysfunction.
20 
Normal bleeding  
time is 1 to 6  minutes. 
16
 
Bleeding time was not effective to use it as screening test. It should also be 
noted that normal bleeding time does not exclude a bleeding disorder. This was 
published by American Society of Clinical Pathologists 
21  
Clotting Time 
Clotting time can be determined by several methods. Blood is collected in a 
clean glass test tube and the tube is moved back and forth at about 37°C about every 
30 seconds until clotting occurs. By this method, the normal clotting time is 6 to 10 
minutes.
17 
Platelet Count 
Platelets help in the formation of platelet plug which helps in initial hemostasis. 
Thrombocytopenia can result in bleeding from microvasculature. In patients who 
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received massive blood transfusion, the platelet count should be maintained at 
50,000/mL or higher. This decreases microvascular bleeding.
12,22  
In previous studies 
with trauma patients have demonstrated attenuation of platelet stimulation to ADP 
agonist for patients in haemorrhagic shock
 23
, and after head injury 
24
 there is also the 
diminished platelet response to ADP, more prominent in nonsurvivors  than survivors 
after life-threatening injury
.25 
Prothrombin Time (PT)  
The integrity of extrinsic pathway of coagulation and common pathway 
involved in coagulation can be established by the Prothrombin time. To determine 
prothrombin time, excess tissue factor (tissue thromboplastin) is added to plasma. This 
test circumvents the intrinsic pathway. As the tissue thromboplastin contains 
phospholipids, it can act as a substitute for platelet. Thus the results of this test are not 
affected by decreased platelet count. PT can be used to control oral anti-coagulant 
therapy. When the plasma levels of one of the factors involved in these two pathways 
are <10% of  normal, PT  gets prolonged. It is more sensitive to deficiencies of factors 
VII and X.
26
 
With most of the rabbit thromboplastin (thromboplastin obtained from rabbit 
brain) the normal range of the PT is between 11 and 14 seconds; when recombinant 
human thromboplastin is used, the range becomes shorter (10–12 seconds).19 
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Activated Partial Thromboplastin Time ( aPTT) 
The activated partial tissue thromboplastin time (aPTT) is a coagulation test 
which checks defect in intrinsic pathway and common pathway of blood clotting 
mechanism. Plasma and a phospholipid platelet substitute (partial thromboplastin) 
are mixed, recalcified, and the rate of formation of fibrin is noted as end point. This 
needs the factors involved in the intrinsic pathway and the factors of common 
pathway to be present in normal amounts. This forms the basis of aPTT.
27  
Platelet substitutes are powerless to activate the extrinsic pathway, which 
requires complete tissue thromboplastin (tissue factor). Thus, the aPTT does not get 
changed in factor VII deficiency.  
Factor VIII and IX deficiencies can be easily picked up by aPTT than factors 
of intrinsic pathway and common pathway. This test becomes abnormal only if the 
plasma level of any one of the factors mentioned above is <15% to 30% of the 
normal value.
27-28
  
The normal range is typically 26–40 seconds. The common causes of a 
prolonged aPTT are as follows: 
1. Diseases affecting liver 
2. Disseminated intravascular coagulation 
3. Transfusion with red blood cells alone (plasma- depleted) 
4. Administration of heparin or other anticoagulants 
5. A circulating anticoagulant (inhibitor) 
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6. Deficiency of a coagulation factor other than factor VII. 
         The aPTT gets prolonged moderately with oral anticoagulant therapy and 
in vitamin K deficiency.
19 
Fibrinogen 
Fibrinogen is a large dimeric protein; each monomer consists of three 
polypeptides like Aα, Bβ and γ which are held together by 12 disulphide bonds. 
Fibrinogen is derived from endocytosis of plasma fibrinogen mediated by 
glycoprotein IIb IIIa and get stored in alpha granules. Fibrin is formed from 
fibrinogen by thrombin cleavage releasing the A and B peptides from fibrinogen.
29
 
The principle behind the Fibrinogen Assay by Clauss Technique is as follows. 
Strong thrombin solution is added to diluted plasma (The plasma must be diluted so 
that, inhibitors like FDPs and heparin also get diluted). A strong thrombin solution is 
also a major requisite to be used so that the clotting time is independent of the 
thrombin concentration.
30
 The normal range is approximately 1.8–3.6 g/l or 200 to 
400 mg/dl.
31 
o MARKERS OF FIBRINOLYSIS 
Fibrin Degradation Products (FDP) 
The proteolytic action of plasmin on fibrinogen yields Fibrin degradation 
products (FDPs). DIC and fibrinolysis are associated with Plasma levels of are 
increased FDP.
32 
Healthy subjects have an FDP concentration of less than 10 mg/ml. 
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Concentrations between 10 and 40 mg/ml are found in acute venous 
thromboembolism, acute myocardial infarction and after major surgery. High levels 
are seen in systemic fibrinolysis associated with DIC and thrombolytic therapy with 
streptokinase.
19
 
D – Dimer 
 D-dimer is a non-invasive and rapid test routinely used to evaluate for 
pulmonary embolism.
33
 But it has low specificity and this limits the usefulness of D-
dimer testing. Specificity of this test is between 40% and 60% and this can lead to 
more number of false- positive results.
34
 Increased fibrinolysis in trauma patients 
proved to be correlated with the severity of injury.
35
 Whenever there is aggressive 
fibrinolysis, it manifests as increase in D-dimer levels. Thus the blood clot becomes 
soluble. Subsequently, exhaustion of coagulation factors and fibrinogen leads to the 
development of disseminated intravascular coagulation (DIC).
36
 
Normal levels should be less than 200 mg/ml.
19
 Positive D-dimer can be in 
Pulmonary Embolism, deep vein thrombosis (DVT), old age, malignancy, and 
pregnancy.
37-43
 
o BASE DEFICIT INDICATORS 
Arterial Blood Gas Analysis 
Arterial blood gas is used to measure the following parameters: 
 
 40 
 
 pH 
 PCO2  
 PO2  
 CO2  
 [HCO3
–
]  
 Normal values for Arterial Blood Gas Analysis 
 [HCO3
–
]    22–30 meq/L 
 PCO2     32–45 mm Hg 
 pH      7.35–7.45 
 PO2     72–104 mm Hg  44 
Base excess or base deficit 
Total amount of base (in mille moles) that is needed to titrate one liter of blood 
in arteries to 7.40 as pH is known as base deficit. In 1960 Anderson and Engel were 
the first people who recommended that Base deficit can be used to find the extent of 
metabolic acidosis. Modified Van Slyke equation is used to find the standard base 
deficit (BD).
45 
 
Previous studies have correlated base deficit with severity of injury and amount 
of blood loss based on data from both animals and human beings.
46-50   
 
The base deficit can be used as an indicator of severity of illness because in 
hemorrhage and hypotension, oxygen delivery to the tissues becomes insufficient. 
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This forces the inception of anaerobic metabolism which causes lactic acid to 
accumulate.
51
 Large amounts of iv fluids administration during resuscitation can also 
affect the base deficit .
52
 
Serum Lactate 
Lactate levels can be used as a surrogate to assess the severity of illness and to 
measure the response to therapeutic interventions.
53
 Lactate is produced in highest 
level in muscle even though it is formed by most tissues. 
54-55 
Under normal 
conditions, liver clears lactate from the blood rapidly, with a small amount of 
additional clearance by the kidneys.
54,56 
 
Normal value:   
 Lactate in arterial blood 0.5–1.6 mmol/L or 4.5–14.4 mg/dL   
 Lactate in venous blood 0.5–2.2 mmol/L or 4.5–19.8 mg/dL 44 
Hypoperfusion as a result of blood loss, is common amongst patients with 
trauma.
57 
The presence of vital sign abnormalities may help to identify shock but their 
absence does not exclude occult hypoperfusion.
58
 Elevated  lactate levels  may help to 
identify concealed ongoing tissue hypoperfusion.
59
 
The level of lactate elevation and lactate clearance rate correlates strongly with 
the risk of multi-organ dysfunction and mortality after trauma. Lactate clearance can 
also be used as an endpoint to guide resuscitation. 
60 -62  
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ETIOLOGY OF TRAUMATIC COAGULOPATHY 
The coagulopathy in trauma is complex in origin. Frequently, they are caused 
by interconnected factors. Some of them are specified below  
Etiologies 
o Clotting factors dilution 
o Hypothermia 
o Enzyme function of coagulation factor get reduced 
o dysfunction of Platelet  
o Increased Fibrinolysis 
o Trauma 
o Head trauma can result in Disseminated Intravascular Coagulation 
o Warfarin therapy 
o Liver diseases 
o Coagulation disorders like 
o Haemophilia 
o von Willebrand disease63 
Dilution 
It is apparent that when enormous intravenous fluid and packed cells are 
transfused to the patients, the coagulation factors in the plasma will be diluted.
64
 Many 
studies have already proven that dilution is often not a problem until the patient is 
infused with 10 to 12 units of red cells 
65- 66.
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Hypothermia 
Patients with traumatic injury are liable to hypothermia.
67,68
 Patients may be at 
accidental site for a long period of time and may present with hypothermia on 
admission.
69
 Infusion of one unit of packed red cells stored at 4°C can decrease the 
core body temperature by 0.25°C.
70
 When the i.v fluids are infused at room 
temperature, for every litre infused the temperature is lowered by 0.5°C. Exposure of 
visceral organs at the time of surgery can result in profound hypothermia. 
Hypothermia has intense effects on the coagulation which can in turn result in clinical 
bleeding.
67, 71, 72
  Enzymes required for coagulation are temperature dependent. Even 
mild cooling can render the patient coagulopathic by affecting the enzymatic 
reactions.  
Rohrer showed that the activated partial thromboplastin time (aPTT) 
prolonged to 39 seconds at 34°C and to 46 seconds at 31°C from normal 36 seconds at 
37°C .
73
 Submissive hypothermia can affect functions of platelet. It can also kindle 
fibrinolysis. Thus, bleeding can be increased significantly even with modest 
hypothermia.
71, 74
 
Trauma 
The main stimulus for blood coagulation is tissue injury.
75- 76
 Patients with 
severe  injuries to brain frequently have severe defibrination due to the release of  
thromboplastin from brain tissue. These patients will suffer from relentlessly disturbed 
haemostasis characterized by plasma fibrinogen less than 50 mg/dL. They may have 
DIC and this can lead to increased blood products transfusion.  
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As coagulation factors are synthesized in liver, severe liver injury or significant 
shock can also lead to failure to compensate for consumption of coagulation      
factors. 
77- 78
 
Underlying disease 
Haemophilia patients may have significant bleeding with their injuries. 
Patients taking oral anticoagulants, patients with liver disease are challenging and 
have ominously higher mortality with trauma.
79-80 
Patients suffering from liver disease 
have several coagulation defects.
81
 Liver synthesize many coagulation factors and 
inhibitors, except factor VIII and  vWF. Liver disease can be associated with decrease 
in plasma levels of inhibitors of fibrinolysis.  
Most common inherited coagulation defects is von Willebrand disease, which 
is associated with tireless bleeding subsequently after trauma.
82
  One in 10,000 male 
patients is having haemophilia.
83
 These patients may continue to bleed unless 
particular deficient factor replacement is given. 
Approximately 1% of the population are on anticoagulation therapy with 
warfarin. Warfarin treatment has higher morbidity and mortality when they present 
with intracranial haemorrhage was reported by several studies.
84 - 85
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PATHOPHYSIOLOGY OF TRAUMATIC COAGULOPATHY 
 
 
Figure 11 – Lethal Triad or triad of death 
 
Hypothermia 
 Normal human body temperature is between the range of 35.6 – 37.8 ̊ C. Core 
temperature < 35 ̊ C can be defined as hypothermia.86 Core temperature < 32° C can 
result in 100% mortality irrespective of degree of shock, injury severity or volume of 
iv fluids administered. This was already proven by a study.
87
 Even mild hypothermia 
can alter the coagulation system in trauma patients.
88
 As already explained, the 
coagulation involves various temperature and pH-dependent complex enzymatic 
reactions.
89
 
Coagulopathy can be defined as a comprehensive group of disease states that 
results in decreased capability of this coagulation system.
86 
It has been established that 
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hypothermia decreases the body’s ability to arrest bleeding. This may due to platelet 
dysfunction, coagulation system, and incongruous activation of clot breakdown. 
Hypothermia in trauma can occur due to many factors. Hemorrhagic shock 
and traumatic brain injury can impair the regulation of core body temperature.
89  
Normal saline at room temperature is hypothermic when compared to our 
body temperature. Thus, resuscitation with huge volume of IV fluids in room 
temperature can significantly contribute to hypothermia and death. 
Acidosis 
     A pH level is a measure of H
+
 concentration. A normal pH ranges from 
7.35–7.45. This is maintained by equilibrium between hydrogen ions concentration 
(acids) and buffers. This balance is meticulously under the control of lungs and 
kidney. 
Arterial pH < 7.35 is defined as acidosis. In patients with trauma the major 
cause for acidosis is tissue hypoperfusion. Anemia from hemorrhage, vasoconstriction 
of peripheral vessels due to hypothermia and hemorrhage can lead to inadequate 
oxygen delivery to the tissues. This creates a disproportion between oxygen demand 
and oxygen delivery. Thus, the cells in the body are enforced to use anaerobic 
metabolism which ends up in the lactic acid accumulation.
90
 
Acidosis can occur in patients who are given normal saline which is an 
unbalanced crystalloid solution.
91
 The pH of normal saline is around 5.5, which is 
extremely acidic than the pH 7.34 (arterial blood). Infusion of normal saline in large 
amount can result in hyperchloremic metabolic acidosis.
[92]
 This can produce an added 
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effect on the existing lactic acidosis in trauma patients. Furthermore, it is also proven 
that increase in systemic tissue inflammation with excessive use of normal saline also 
support to the traumatic coagulopathy.
92
 Ringer Lactate with pH 6.5 is discordant with 
several medications and blood products. 
Lastly, hypoventilation due to obstruction to the respiratory passage or 
respiratory depression in a trauma patient may result in hypercapnia (increased CO2 
levels) and thus respiratory acidosis. Narcotic abuse, alcohol intoxication, traumatic 
injuries to brain, flail chest or previous history of lung diseases such as chronic 
obstructive pulmonary disease can also result in respiratory acidosis.  
Severe acidemia (pH < 7.20), results in many disastrous consequences like 
impairment of coagulation system.
93
 The decrease in pH from 7.4 to 7.0 reduced the 
efficacy of the coagulation system by 55–70% was proven already. 94 
Coagulopathy 
   Coagulopathy has a potential to create a continued hemorrhage in the bleeding 
trauma patient regardless of a specific cause. 
Coagulopathy is associated with a four-fold increase in mortality.
8, 14, 95
 This 
can occur due to several causes like hypothermia, acidosis, clotting factors loss 
through bleeding, hemodilution, and the utilization of clotting factors by our body and 
following that there occurs depletion of both platelets and clotting factors.
90
 
Infusion of normal saline and packed red blood cells in huge amount further 
dilutes the residual clotting factors in the circulation. In addition there occurs 
abnormal activation of the clotting cascade, causing undue formation of blood clot and 
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increased fibrinolysis. This occurs in disproportion to the injury in a patient with 
severe trauma.
91
 Thus abnormal activation of the blood coagulation system swiftly 
ingests the left out clotting factors in the body. This further leads to augmented 
deficiency of the important factors required to achieve hemostasis. 
The exact mechanism behind this coagulopathy is systemic anticoagulation due 
to protein C activation and enhanced fibrinolysis.  
 
Protein C Activation 
Brohi.K et al showed that hypoperfusion is directly proportional to the severity 
of injury and associated with thrombomodulin increase and protein C decrease.
6
  
Theoretically, trauma activates the extrinsic pathway in the absence of hypo 
perfusion as shown in Figure12.  
 
Figure 12 : Mechanism of Acute Traumatic Coagulopathy 
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In the existence of tissue hypoperfusion, thrombomodulin and thrombin 
complex distract it to act as an anticoagulant. This complex activates protein C. 
Protein C gets activated and inhibits the extrinsic pathway by causing proteolysis of 
factor V and VIII (Figure 13). 
96. 
 
Enhanced fibrinolysis 
 
Trauma can lead to enhanced fibrinolytic activity. Increased D-dimer levels 
following traumatic injury have been recognized by other studies.
6, 97 
Release of tissue 
plasminogen activator (tPA) following injury results in fibrinolysis.
98-100
 Regulator to 
diminish the propagation of blood clot to undamaged area is tPA. 
6
 
   Tissue hypoperfusion decreases the level of plasminogen activator inhibitor-1 
(PAI-1) . Activated protein C in excess will ingest more and more PAI-1
101
 and thus 
leads to increased fibrinolysis. This is shown in Figure 13.
96 
 
Figure 13 : Process of Hyperfibrinolysis 
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HISTORY : 
John H Seigel et al (1990) studied the importance of variables like Glasgow 
Coma Score, base excess (or deficit), lactate level, Injury Severity Score and 
replacement of blood volume in patients with trauma. They conducted a study with 
185 blunt liver trauma. Both base excess and initial 24-hour volume of blood 
transfusion reflected the probability of death and found to be highly significant. This 
was tested on data from 323 additional patients showed it to be a highly significant 
early predictor of outcome.
 102
 
Davis J W et al (1996) observed that the transfusion requirements increased 
significantly as the Base Deficit category became more severe.. Both ICU and period 
of stay in hospital increased significantly with worsening Base Deficit. They also 
reported that as the base deficit increases, the total number cases with shock – related 
complications also increased significantly. They also found that as the Base Deficit 
worsens, mortality also increased significantly. 
Thus they concluded that Base Deficit on admission identifies patients who 
may require early blood transfusion and increased stay in ICU and hospital, and may 
easily develop shock-related complications.
49 
They have not taken into account the 
severity of injury as they included all patients who required blood transfusion.  
 Cosgriff et al (1997) analysed patients who received blood transfusion greater 
than 10 units of packed red cells for 24 hours. According to this study, 27 patients 
(47%) developed life – threatening coagulopathy. They found the following 4 factors 
as risk factors  
 51 
 
1. Temperature less than 34°C  
2. pH less than 7.10  
3. Systolic Blood Pressure less than 70 mm Hg  
4. Injury Severity Score (ISS) more than 25  
 They also found that the probability of developing coagulopathy was 49% 
when there was ISS of more than 25 and Temperature less than 34°C ; with ISS of 
more than 25 and  pH < 7.10 the incidence of coagulopathy was 49%; When all the 
four risk factors mentioned above are present he incidence was 98%.
103
 
 Thus they concluded that coagulopathy in the utterly injured patients who 
require massive blood transfusion can be well predicted by progressive metabolic 
acidosis and persistent hypothermia. They have not mentioned about the severity of 
injury and for acidosis they have taken blood pH alone. Base deficit was not taken into 
consideration. 
 
 
 Brohi K et al (2003) wanted to prove that traumatic coagulopathy can be 
caused principally by IV fluids administration and hypothermia. They observed that 
57.7% patients had an ISS of more than 15; 24.4% of patients had a substantial 
coagulopathy and they also had ominously increased mortality. The incidence of 
coagulopathy increased with injury severity, but was not related to the volume of IV 
fluids given to the patients. They concluded that traumatic coagulopathy is an 
indicator of severity of injury and it is related to mortality.
95 
 They have not considered the fluid administered before hospitalisation which 
may alter the coagulation status.  
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Macleod et al (2003) showed that there were 8.9% overall mortality due to all 
causes. 28% had a prolonged PT and 8% had an abnormal aPTT on arrival to the 
trauma care centre. In patients with normal PT, 6.3% died, as compared with 19.3% 
with an abnormal PT which was statistically significant. They also reported that the 
PT and aPTT can be used as independent predictors of mortality whereas platelet 
count cannot be used. 
Thus they concluded that the frequency of coagulation abnormalities is high 
early after trauma and coagulopathy can be used as an independent predictor of 
mortality.
8 
They have not considered the markers of fibrinolysis to diagnose 
coagulopathy. 
Marc Meagle et al (2006) observed that 34.2% had coagulopathy. The 
incidence for coagulopathy was also increased as the amounts of IV fluids 
administered increased. 29% of patients with coagulopathy developed multi organ 
failure which was also found to be statistically significant.
14
 
Karim Brohi et al (2007) conducted a prospective study with a cohort of 208 
major trauma patients. They found that the patients without tissue hypoperfusion 
didn’t have coagulopathy, irrespective of thrombin generated. Prolonged aPTT and PT 
were detected with an augmented Base Deficit.  They also published that the 
increasing Base Deficit and mortality was related with high thrombomodulin and 
decreased protein C. They concluded that in the presence of tissue hypo perfusion 
traumatic coagulopathy occurs early.
6
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Park et al (2008) conducted a study with 53 patients. Among these 15 
patients died. They proved that the combined use of markers of coagulation and 
standard clinical indices will help to predict the mortality irrespective of type of injury 
(burned and non-burned)
104
 
  Duchesne et al (2009) conducted a study of patients with diagnosis of TIC 
after packed cells transfusion of more than 10 units during surgery.   They concluded 
that Trauma Induced Coagulopathy is very common after severe injury and also 
associated with mortality in patients who had transfusion of more than10 units. 
105
 
 Hess et al (2009) conducted a study with trauma patients and found that 
abnormal coagulation tests were increasingly reported as the severity of injury 
increases. The abnormal PT ranges from 5% to 43% as the Injury Severity Scores 
increased from 5% to over 45%. Low platelet counts were from 4% to 18 %. 
Abnormalities in coagulation tests were associated with significant mortality and this 
was proved to be true for the aPTT.
106
 
 Victor Jeger et al (2010) studied patients with an Injury Severity Score 
(ISS) of more than or equal to16. They found that out of the 172 patients 32.6% had 
Traumatic coagulopathy at the time of admission .
107
 
 Kanchana Rangarajan et al (2010) studied 48 orthopaedic trauma 
patients. Coagulation parameters and DIC score were evaluated. Out of 48 patients, 
20% had mild increase in DIC scores at the time of admission. Fibrinogen levels alone 
were significantly increased in these patients from the time of admission. No change 
was found in the remaining parameters.
108
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 Sjoerd Greuters et al (2011) conducted a study in patients who had 
Traumatic Brain Injury (TBI) alone. Among these patients 24% suffered from early 
coagulopathy. Thus they confirmed that presence of coagulopathy had been related to 
worse clinical outcome.
109
 
Johansson et al (2011) wanted to investigate the occurrence of overt DIC and 
acute traumatic coagulopathy of shock based on their biomarkers reflecting tissue/ 
endothelial cell/ glycocalyx damage. They reported that 15% had acute traumatic 
coagulopathy whereas no patients had overt DIC. Patients with acute traumatic 
coagulopathy had higher ISS, increased blood transfusion requirements and significant 
mortality. One important finding in this study was with patients without acute 
traumatic coagulopathy, had the same report of biomarkers as that observed in patients 
with acute traumatic coagulopathy.
110
 
Bernard Floccard et al (2012) conducted a study which shows that 56% 
patients had abnormal coagulation tests on scene screening for coagulation profile. 
Activity of Protein C was decreased in patients with coagulopathy group which was 
proved to be significant statistically. 60% of patients had abnormal coagulation tests 
on hospital admission. They concluded that Coagulopathy occurs even prior to 
hospital admission after injury that is before fluid administration. The incidence of 
coagulopathy is high at the accidental site and is related to the injury and not to 
hypoperfusion.
111
 
Erick Mujuni et al (2012) observed that coagulopathy incidence was 54%.  
The ISS mean for the patients with coagulopathy was little higher. Patients with 
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coagulopathy stayed longer in hospital. Coagulopathy was also associated with acute 
renal injury .Mortality was more in the coagulopathy group. They concluded that 
coagulation profile can be used to  predict outcomes in major trauma patients.
112
 
Vijay kanna et al (2013) studied that the Traumatic patients and showed the 
incidence of coagulopathy as 60% in patients with head injury and early blood 
transfusion reversed back the abnormality in coagulation  profile.
113 
 Fei A et al (2015) conducted a study to assess the prognostic value of 
haemostasis-related parameters in patients admitted in ICU. They conclude that FDP 
is the best self-determining pointer of mortality in ICU patients among all other 
parameters examined. When FDP and APACHE II scores were used in concordance, 
it may help to predict mortality in ICU patients.
114
  
 Delano MJ et al (2015) wanted to study the effect of recovery when 
hypertonic solutions were used for coagulopathy after trauma. When patients in shock 
got treated with Normal saline, Tissue factor (TF) was found to be elevated. But when 
treated with hypertonic saline and hypertonic saline with dextran TF was found to be 
decreased. Thus they concluded that when hypertonic saline with Dextran are 
administered during resuscitation it worsens coagulability and may result in increased 
fibrinolysis in patients with haemorrhagic shock after trauma.
115
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MATERIALS AND METHODS 
TYPE OF STUDY   :  
Prospective Cohort study 
SAMPLE SIZE    :  
60 (convenient sample)  
STUDY PERIOD    : 
January 2014 to December 2014 
TIME LINE OF THE STUDY  
(From the inception to the end of the study using Henry Gantt Chart ) 
WORK DONE 
2013 2014 2014 2015 2015 
Oct - Dec Jan - Jun Jul - Dec Jan- May Jun - Sep 
Protocol Preparation       
Ethical Clearance        
Review of Literature   
Data Collection     
Data entry and Analysis       
Thesis Report Writing      
Thesis Submission       
 
STUDY SETTING   : 
 This study was carried out with patients who get admitted in Causality 
department of Chennai Medical College Hospital and Research Centre, after obtaining 
Institute Ethical Committee approval. 
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INCLUSION CRITERIA   :  
 Age – 20 to 60 years. 
 New Trauma case. 
 Glasgow Coma Scale of more than 8/15. 
EXCLUSION CRITERIA   : 
Patients with the following history are excluded. 
 History of Diabetes Mellitus with Chronic Renal Failure and 
Hypertension with Chronic Renal Failure 
 History of liver and cardiac diseases. 
 History of anticoagulant treatment at present. 
 History of valve replacement surgeries. 
 History of taking medications which influence the coagulation 
profile. 
PARAMETERS STUDIED :  
Revised Trauma Score (RTS) is employed to assess the injury severity 
which includes three physiological parameters:  
 Respiratory rate (RR). 
 Glasgow Coma Scale (GCS) and 
 Systolic blood pressure (SBP) 
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 PHYSIOLOGICAL PARAMETERS 
 Body temperature 
 Pulse rate 
 Respiratory rate 
 Blood pressure 
 
 BIOCHEMICAL PARAMETERS 
 Blood Urea  
 Serum Creatinine 
 Bleeding Time 
 Clotting Time 
 Platelet counts 
 Prothrombin Time (PT)  
 Activated Partial Tissue Thromboplastin Time (aPTT) 
 Fibrinogen level  
 Presence of Fibrin Degradation Products (FDP)  
 D – Dimer positivity 
 Arterial Blood Gas Analysis 
 Serum Lactate 
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STUDY TECHNIQUE: 
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STUDY PROCEDURE : 
At the time of admission, after initial stabilization informed written 
consent was got from the patient or his/her relative. Then history was recorded 
patients were included in the study according to the inclusion criteria and exclusion 
criteria mentioned above.  
General examination of the patient was done. Vital signs like 
Temperature, Pulse rate, Respiratory rate, and Blood Pressure were recorded 
manually. Patient was assessed and Glasgow Coma Scale was calculated. Then 
Revised Trauma Score –is considered by the following method 116 
 
COAGULATION TESTS:  
Bleeding time is determined by Duke’s method. Bleeding Time greater than 6 
mins is regarded as abnormal. 
17
 
Venous blood sample (3ml) was collected in vacutainer containing 3.8% 
trisodium citrate and 1 ml in a clean glass test tube.  
Clotting time is determined by blood collected in a clean glass test tube. Then 
the tube is moved back and forth every 30 seconds until the blood is clotted. Clotting 
time more than 10 mins is considered to be abnormal.
17
 
RTS = 0.9368 GCS + 0.7326 SBP + 0.2908 RR 
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 Blood samples were analysed to determine Platelet count using auto analyser. 
(Make - MINIDRAY Model No - 5300). Then remaining blood samples were 
centrifuged at 3000 rpm for 10 minutes to obtain clear plasma.  
Coagulation profile (PT, aPTT) were done by using a coagulation semi – auto 
analyser   (Make - Genera; Model no – 34). 
Prothrombin Time (PT) was determined using a reagent named 
“LIQUIPLASTIN” a rabbit brain thromboplastin. 50 µl of plasma was taken and 
warmed at 37 ̊ C for 2 minutes by keeping it in coagulation analyser. Then the 50 µl 
of rabbit brain thromboplastin reagent is added to the pre warmed plasma sample and 
again kept in the coagulation analyser. The reading given by the analyser is noted as 
the patient’s Prothrombin time. Prothrombin Time more than 14 seconds is 
considered to be abnormal.
19
 
Activated Partial Tissue Thromboplastin Time (aPTT) was determined 
using a reagent named “ Hemostat aPTT - EL ” a Ellagic Acid Activator. 50 µl of 
patient’s plasma was taken and 50 µl of first reagent is added. Gently mixed and 
incubated for 3 minutes at 37 ̊ C. Then second reagent is added by keeping it in the 
coagulation analyser. The reading given by the analyser is noted as the patient’s 
aPTT. aPTT greater than 36 seconds is considered to be abnormal. 
19 
 Fibrinogen assay is done by clot based method using an automated 
coagulation analyser (STA Compact) and the normal value for fibrinogen is 200 to 
400 mg/dL 
30
 
      Fibrin Degradation Products are identified by Protamine sulphate method 
done manually. 500 µL of Plasma kept in the water bath at 37 ̊ C for 2 mins. Then 
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50µL of 1 % Protamine sulphate is added. After 5 minutes the test tube is taken and 
watched for white precipitate. The presence of white precipitate indicates FDP 
positive. This test is based on the principle that it detects the presence of fibrin of 
Fibrin Degradation Products in Plasma. Fibrin acts with protamine sulphate and react 
within 15 minutes. 
 D – Dimer assay is done by chemi – luminescence assay technique. (Make - 
SNIBE MAGLUMINI; Model - 2000) 
2ml arterial blood was collected in a heparinised tube and Arterial Blood Gas 
(ABG) analysis and Lactate was also done by the blood gas analyser.                       
(Make: JEMPREMIER Model: 3000) From the ABG analysis report Base Deficit 
(marker of tissue hypo perfusion) was calculated using a formula mentioned below.
45 
 
Base deficit or excess of 2 mmol /L (mEq/L) is considered to normal.
117 
Base deficit 
> 6 mmol is previously termed as indicator of tissue hypoperfusion.
49 
Arterial lactate 
> 1.6 mmol/L in arterial blood is considered as abnormal.
44
 
Acute renal dysfunction in patients was assessed using Renal Function 
Test like Urea and Creatinine done using a semi – automated analyser. 
 Renal dysfunction was found by the formula given below.
118
 
  
Base deficit = 0.93 x ( ( HCO3
-) – 24.4 + 14.8 x ( pH – 7.4)) 
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Renal function = Blood Urea Nitrogen ( BUN) / Creatinine 
Renal dysfunction is present if the value is greater than 20. 
Blood Urea Nitrogen (BUN) is given by Blood Urea / 2.14 
 
Patients with any of the following results in day 0 or day 2 were termed as 
coagulopathic. 
 Bleeding Time > 6 mins 
 Clotting Time > 10 mins 
 Platelet count < 1.2 lakhs / cu. mm 
 Prothrombin Time when prolonged for more than 14 seconds  
 Activated Partial Thromboplastin Time more than 40 seconds  
 Fibrinogen level of less than 200 mg per dL 
 Positive Fibrin Degradation Product  
 D - Dimer – positive. 
The patients who are recruited into the study were monitored and studied on 
days 0, 2, 6, and 14. Outcome variables like mortality, renal dysfunction, Length of 
stay in hospital and routine physiological parameters were established and 
documented during these periods.  
     Patients were tracked upon till the time of discharge. Patients who were 
getting discharged during this period were considered to be survivors. 
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PHOTOS 
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METHOD OF STATISTICAL ANALYSIS 
The data is entered in Microsoft Excel and exported to SPSS version 22. 
Appropriate statistical analysis is carried out by using Statistical Package for Social 
Science (SPSS). Both descriptive and inference statistical analysis is used to analyse 
the data. The descriptive data is presented as frequencies and proportions. The 
continuous data is presented as Mean with Standard Deviation. Univariate logistic 
regression is applied to establish the association between the independent variables 
and dependent (Outcome) variables like Morbidity, Mortality and complications like 
Acute Renal Injury. Those which are significant in univariate analysis were taken for 
multiple logistic regression model.  
All the statistical analysis will be carried out at 5% level of significance and p 
value of less than or equal to 0.05 will be regarded as significant. 
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RESULTS 
Totally 60 patients with both major and minor trauma were enrolled into the 
study from casualty between the months of January 2014 to December 2014. Their 
initial coagulation profile was determined and they were monitored up for two weeks 
to establish their primary clinical outcomes. Of these 2 patients (3.3%) got discharged 
against medical advice, moved to other hospital. Therefore only 58 patients were taken 
for analysis. 
 Demographic details and the socioeconomic details of the study 
population is given by table 1. 
 
Table 1 : Demographic distribution of the data 
PARAMETERS 
FREQUENCY 
(n = 58) 
 
PERCENTAGE 
(100%) 
 
GENDER DISTRIBUTION  
Male 44 
 
75.86 % 
 
Female 14 24.13 % 
AGE DISTRIBUTION ( Based on age group ) 
21 – 30 Years 18 31.0 % 
31 – 40 Years 21 36.2 % 
41 – 50 Years 6 10.3 % 
51 – 60 Years 13 22.4 % 
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EDUCATIONAL STATUS 
No education 8 13.8 % 
Primary education 20 34.5 % 
Secondary education 10 17.2 % 
Graduate / higher 20 34.5 % 
 
44 patients (76%) were male and 14 patients (24%) were female (Table 1) 
Patients were between age 20 and 60 years with a mean age of 38.53 + 12.0 years. 
There were more number of patients in age group between 31 to 40 years.  
The 34.5 % of the patients had primary education 34.5 % graduates or higher followed 
by 19 % had secondary education and 13.8 % patients were uneducated. 
 
 
 
 
PARAMETERS 
FREQUENCY 
(n = 58) 
 
PERCENTAGE 
(100%) 
 
OCCUPATIONAL STATUS 
Employed/ Salaried 24 41.1 % 
Students 8 13.8 % 
Business 9 15.5 % 
Unemployed 17 29.3 % 
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Table 2 : Distribution of other data 
PARAMETERS FREQUENCY 
 
PERCENTAGE 
 
TYPE OF INJURY 
Blunt Injury 48 82.8 % 
Penetrating Injury 10 17.2 % 
CAUSE OF INJURY 
Road Traffic Accident 39 67.2 % 
Fall 10 17.2 % 
Other cause of Injury 9 15.5 % 
COAGULATION STATUS 
Coagulopathy Present 20 34.5 % 
Coagulopathy Absent 38 65.5 % 
 
Regarding the type of injury 10 patients (17.2%) presented with blunt injury 
the commonest and 38 patients (65.5 %) with penetrating injury. The mode of injury 
which had occurred commonly is Road Traffic Accident. This includes 39 patients 
(67.2 %), which is followed by fall from height 10 patients (17.2 %) and other mode 
of injury 9 patients (15.5%). Coagulopathy was present in 20 patients (34.5%) 
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Chart 1 : Status of Coagulopathy in the study population 
regarded as 
 
Table 3 : Status of Co-morbid conditions and Blood Transfusion 
PARAMETERS FREQUENCY PERCENTAGE 
BLOOD TRANSFUSION 
Given 17 29. 3 % 
Not Given 41 70.7 % 
DIABETES MELLITUS 
Present 17 29.3 % 
Absent 41 70.7 % 
HYPERTENSION 
Present 13 22.4 % 
Absent 45 77.6 % 
 
 
. In total blood transfusion was given 17 (29.3 %) patients. Overall 17 (29.3%) 
patients were diabetic and 13 (22.4%) patients were hypertensive patients  
 
Table 4 :  Distribution of Outcome parameters  
PARAMETER FREQUENCY PERCENTAGE 
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Among 58 patients, 7 (12.1%) patients had acute renal injury based on the 
ratio of Blood urea nitrogen and Serum creatinine.  
Overall mortality is 10.3% i.e 6 (15.5%) patients in the study population. 9 
patients had base deficit > 6 mmol /L and suffered from tissue hypoperfusion and 49 
patients had Base deficit below 6 mmol/ L. 
Morbidity was assessed using the total length of stay of the trauma patient 
either in the ward or ICU. For this analysis, the patients who survived during the 
follow up period were only included. Median was found to be 11 for the extent of stay 
in hospital (days). Then the patients were categorised into < 11 days and > 11 days. 
30 (57.7%) patients stayed for > 11 days and 22 (42.3%) patients stayed for less than 
11 days. 
 
Table 5 : Distribution of different parameters of Coagulation profile  
ACUTE RENAL INJURY 
Present 7 12.1 % 
Absent 51 87.9 % 
MORTALITY STATISTICS 
Dead 6 10.3 % 
Survived 52 89.7 % 
LENGTH OF STAY IN ( Based on No. of Patients who survived – (52)) 
Greater than or equal to 11 days 30 57.7 % 
Less than 11 days 22 42.3 % 
Parameters Studied 
Normal Results 
No. of Patients 
Abnormal 
Results 
Mean + SD 
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Out of 58 patients, 49 patients had normal Platelet count & 54 patients had 
normal Bleeding Time and only 9 patients had low platelet count and 4 patients had 
prolonged bleeding time. 20 patients (37.5 %) out of 58 patients with trauma had 
elevated PT. A total of 9 patients had elevated aPTT. 9 (15.5%) patients had decreased 
fibrinogen 
 
 
 
Chart 2 : Status of coagulation Profile and D – Dimer results 
( %) No. of Patients 
(%) 
COAGULATION PROFILE 
Platelet Count 49 (84.5%) 9 (15.5 %) 2.22 + 0.35 
Bleeding Time 54 (93.1 %) 4 (6.90%)        4.10 + 0.28 
Clotting Time       49 (84.5 %) 9 (15.5%) 6.81 + 0.26 
Prothrombin Time 38 (65.5 %) 20 (34.5%) 14.1 + 0.32 
aPTT 49 (84.5 %) 9 (15.5 %) 31.32 + 0.25 
Fibrinogen 49 (84.5%) 9 (15.5 %) 271.34 + 16.48 
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Table 6: Distribution of markers of hyperfibrinolysis and tissue hypoperfusion 
 
6 (10.4%) patients had FDP positive and 8 (13.8 %) patients had D - dimer positive. 
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STUDY PARAMETER 
STATUS OF COAGULATION PROFILE AND D- DIMER 
NORMAL
ABNORMAL
Parameters Studied 
Normal Results 
No. of Patients 
( %) 
Abnormal Results 
No. of Patients 
(%) 
Mean + SD 
MARKERS OF HYPERFIBRINOLYSIS 
Fibrin Degradation Product 52 (89.6%) 6 (10.4%) - 
D – Dimer 50 (86.2%) 8 (13.8%) - 
MARKERS OF TISSUE HYPOPERFUSION 
Base Deficit 49 (84.5%) 9 (15.5 %) - 2.32 + 0.33 
Serum Lactate 52 (89.6%) 6 (10.4%) 1.29 + 0.21 
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Base deficit of -6 mmol/L or greater was observed in 49 patients (84.5%) and 
elevated serum lactate was observed in 52 patients (89.6%).  
 
Table 7: Univariate analysis showing association of independent variables with 
Coagulopathy 
 
Independent Variable 
Coagulopathy 
Present 
No. of Patients 
(%) 
p Value 95 % CI 
Gender 
Male (44) 14 (31.8 %) 0.45 0.6 ( 0.1 - 2.1) 
Female (14) 6 (42.8 %) - 1 
Age (Continuous Variable) 
Age  0.27 0.9 (0.9 – 1.021) 
Type of Injury 
Blunt Injury (48) 15 (31.2 %) 0.26 2.2 (0.55 - 8.7) 
Penetrating Injury ( 10) 5 (50 %) -         1 
Diabetes Mellitus 
Present (17) 5 (29.4%) 0.7 0.7 ( 0.21 – 2.4) 
Absent (41) 15 (36.6%) -        1 
Hypertension 
Present (13) 6 (46.1%) 0.3 1.8 ( 0.5 - 6.6) 
Absent (45) 14 (31.1%) -       1 
 
Value of p less than or equal to 0.05 is regarded as significance. 
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The age when regarded as a continuous variable, there was no significance 
between the age and presence of coagulopathy.  
Among the patients with coagulopathy 14 were male and 6 were female. There 
was no significant association between the gender and the coagulopathy 
(p=0.45).Though there were more number of patients with blunt injury having 
coagulopathy, there was no significant association between type of injury and 
coagulopathy. (p value = 0.26)  
When Diabetes Mellitus and Hypertension was considered, there was no 
significant association with coagulopathy. p value was found to be 0.7 and 0.3 
respectively.  
 
Table 8: Univariate analysis showing association of Tissue hypoperfusion and 
severity of Injury with coagulopathy 
 
Independent 
Variable 
Coagulopathy Present 
No. of Patients 
(%) 
p Value OR (95 % CI) 
Tissue hypoperfusion 
Present (9) 7 (%) 0.003** 18.8 (2.72 – 129.73) 
Absent (49) 13 (%)  1 
Severity of Injury ( Continuous Variable ) 
Revised Trauma Score - 0.04* 0.63 (0.4 – 0.9) 
 
Value of p less than or equal to 0.05 is taken as significance. Value of p less than or 
equal to 0.01 is regarded as highly significant. 
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Based on the results of base deficit, tissue hypoperfusion was present in 9 patients in 
total. Among these patients 7 patients (77.7%) had coagulopathy. Thus, tissue 
hypoperfusion was also significantly associated with the presence of coagulopathy. 
The p value was found to be statistically significant (p= 0.003)   
The mean Revised Trauma Score was 6.57 + 1.22 among total trauma patients. 
There was a significant association between the severity of injury and the presence of 
the coagulopathy with p value of 0.04.  
 
Table 9 : Univariate analysis showing association between Coagulopathy and blood 
transfusion  
Independent 
Variable 
Blood Transfusion 
given 
 p Value OR (95 % CI) 
COAGULOPATHY 
Present (20) 12 (60%)         0.01*    9.9 ( 2.72 – 36.25 ) 
Absent (38) 5 (16.6%)  1 
 
 
* p value of less than or equal to0.05 is regarded as significant. ** p value of less than 
or equal to 0.01 is regarded as highly significant. 
  
Traumatic coagulopathy was associated with increased blood transfusion 
requirements and proved to be statistically significant. (p = 0.01)  
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Table 10: Univariate analysis showing association of Independent variables and 
Mortality 
Independent 
Variable 
Mortality 
No. of Patients 
(%) 
P Value OR (95 % CI) 
Gender 
Male (44) 4 0.58 0.6 (0.09 – 3.6) 
Female (14) 2  1 
Age ( Continuous variable) 
Age - 0.49 0.97 (0.9 – 1.05) 
Severity of Injury ( Continuous Variable ) 
RTS  0.043* 0.13 (0.02 – 0.93) 
Coagulopathy 
Present (20) 5 ( 40.0 %) 0.027* 12.3 (1.3 – 114.6) 
Absent (38) 1 ( 2.63%)  1 
Renal injury 
Present (7) 3 ( 42.8 %) 0.01* 12 (1.8 – 80.04) 
Absent (51) 3 (5.88 %)  1 
Tissue Hypoperfusion (Based on Base Deficit) 
Present (9) 5 ( 55.5 %) 0.028* 7.7(1.25 – 46.95 ) 
Absent (49) 1 ( 2.04 %)  1 
Serum Lactate 
Present (6) 4 (66.6%) 0.01* 12 (1.8 – 80.02) 
Absent (52) 2 (3.84%)  1 
 
* p value of less than or equal to 0.05 is regarded as significant. ** p value of less than 
or equal to 0.01 is regarded as highly significant. 
 
 
 77 
 
Among the 6 patients who died during the period of follow up, 4 were male 
and 2 were female. There was no significant association between the gender and the 
mortality (p valve =0.58). Age when regarded as a continuous variable, there was no 
significant difference between the age and mortality.  
There was a significant association between the severity of injury and 
mortality with p value of 0.043. (SD - 0.13 95% CI (0.02 – 0.93)) 
Mortality was more among the patients with coagulopathy (5 patients (40%)) 
than patients without coagulopathy (1 patient (2.6%)). The p value was found to be 
statistically significant (p= 0.027) (OR 12.3 95 % CI (1.3 – 114.6)) 
Based on the ratio of blood urea nitrogen to serum creatinine, in total 7 
(12.1%) patients had Renal injury. Among these 7 patients, 3 (42.8 %) died. The 
association of renal injury and mortality is proved to be significant (p value = 0.01)  
Out of 9 patients with tissue hypoperfusion, 5 patients (55.5%) died either on 
the day of trauma or on the second day. The association of tissue hypo perfusion and 
mortality. The p value was found to be statistically significant (p= 0.028)  
Serum lactate was found to be abnormal for 6 (10.34%) patients in total. In 
this, 4 (66.6%) patients died during the period of follow up. The association of serum 
lactate and mortality was found to be statistically significant (p= 0.01) 
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Table 11: Univariate analysis showing association of Independent parameters of 
Coagulation Profile and Mortality 
 
* Value of p less than or equal to 0.05 is regarded as significant. ** Value of p less 
than or equal to 0.01 is regarded as highly significant. 
 
 
Independent Variable 
Mortality 
No. of 
Patients 
(%) 
P Value OR (95 % CI) 
Platelet Count 
Abnormal (9) 3 (33.3%) 0.028* 7.6 (1.25 – 46.9) 
Normal ( 49) 3 (6.10%)  1 
Prothrombin Time 
Abnormal (20) 5(25.0%) 0.027* 12.3 ( 1.3 – 114.6) 
Normal (38) 1(2.63%)  1 
aPTT    
Abnormal (9) 5(55.5%) 0.003* 18.8 (2.72 – 129.7) 
Normal (49) 1(2.04%)  1 
Fibrinogen    
Abnormal (9) 3(33.3%) 0.028* 7.6 (1.25 – 46.95) 
Normal (49) 3(6.12%)  1 
Fibrin Degradation Products 
Positive (5) 2(40.0%) 0.046* 8.16 (1.04 – 64.02) 
Negative (52) 4(7.69%)  1 
D – Dimer 
Positive (8) 3(37.5%) 0.017* 9.4(1.48- 59.59) 
Negative (50) 3(6.00%)          1 
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Out of 9 patients who had abnormal Platelet count 3 patients i.e 33.3 % died 
during the period of follow up for 14 days. The p value of 0.028 was found to be 
statistically significant (SD 7.6 95% CI (1.25 – 46.9))   
 Among 20 patients with elevated PT, 5 patients i.e 25 % died either on day 0 
or day 2. The p value was found to 0.027 which was proved to be statistically 
significant. (SD 12.3 95% CI (1.3 – 114.6))   
 In 9 patients with elevated aPTT, 5 patients (55.5%) died. There was a 
significant association between aPTT and mortality with p value of 0.003. 3 (6%) 
patients of the total 9 patients with decreased fibrinogen, died. This was also proved 
to be statistically significant with p value – 0.028.  
2 out of 6 patients with FDP positive died which was significant statistically 
with p value of 0.046. Among 8 patients with D - dimer positive, 3 patients died 
during the follow up period. This also showed a significant association between D - 
Dimer levels and mortality. The p value was found to be 0.017. 
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Table 12: Univariate analysis showing association of Independent variables and length 
of stay in the hospital 
Independent 
Variable 
Length of Stay 
>= 11 days 
p Value OR (95 % CI) 
Tissue hypoperfusion 
Present (4) 3 (75%) 0.47 2.3 (0.22 – 24.07) 
Absent (48) 27 (56.5%)              1 
Renal injury 
Present (3) 3 (100%) - - 
Absent (49) 0  1 
Coagulopathy 
Present (15) 12 (80 %) 0.047* 4.22 (1.02 – 17.46) 
Absent (37) 18 (48.6%)  1 
 
Analysis done with 52 patients who survived; * Value of p less than or equal to 0.05 is 
regarded as significant. **p value of less than or equal to 0.01 is regarded as highly 
significant. 
 
Among 4 patients with tissue hypoperfusion who survived, 3 (75%) patients 
stayed longer in the ward for >= 11 days than patients without tissue hypoperfusion. 
The p value was not found to be statistically significant ( p = 0.47)   
Out of 3 patients with acute renal injury who survived during the follow up 
period, all the 3 (100%) patients stayed longer in the ward for >= 11 days than 
patients without renal injury.  
Out of 15 patients with coagulopathy who survived during the follow up 
period, 12 patients stayed in the ward for >= 11 days than patients without 
 81 
 
coagulopathy. The p value was found to be statistically significant (p = 0.047) and 
proved that there is association of coagulopathy and length of stay. 
Chart 3 : Distribution of various  parameters in relation to Morbidity  ( Length of stay 
>= 11 days ) 
 
 
 
Chart 3 shows the distribution of various other parameters in relation to 
morbidity. (i.e) length of stay >= 11 days 
Table 13: Univariate analysis showing association of Tissue hypoperfusion  and 
Severity of Injury 
  
Independent 
Variable 
Tissue hypoperfusion 
present 
p Value OR (95 % CI) 
RTS ( Continuous 
Variable ) 
- 0.007** 2.3 (0.22 – 24.07) 
 
*p value of less than or equal to0.05 is regarded as significant. **p value of less than 
or equal to 0.01 is regarded as highly significant. 
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Severity of Injury was determined using Revised Trauma Scale. When RTS was 
regarded as a continuous variable, it was significantly associated with Tissue 
hypoperfusion.  (p = 0.007) 
  
Table 14: Univariate analysis showing association of High Lactate level and 
Severity of Injury 
Independent 
Variable 
High Lactate level p Value OR (95 % CI) 
RTS ( Continuous 
Variable ) 
- 0.037* 0.34 (0.13 – 0.93) 
 
*p value of less than or equal to 0.05 is regarded as significant. **p value of less than 
or equal to 0.01 is regarded as highly significant. 
 
The elevated lactate level was also found to be significantly associated with severity 
of injury.( p – 0.037) 
 
Table 15 : Univariate analysis showing association of Presence of Renal Injury 
and Severity of Injury 
 
Independent 
Variable 
Presence of Renal 
Injury 
p Value OR (95 % CI) 
RTS ( Continuous 
Variable ) 
- 0.05 0.72 (0.26 – 0.89) 
 
*p value of less than or equal to 0.05 is regarded as significant. **p value of less than 
or equal to 0.01 is regarded as highly significant. 
 
As the severity of injury increase, the presence of acute renal injury is also more. Thus 
acute renal injury and severity of injury was also just associated with p value 0.05 
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Table 16 : Univariate analysis model showing association of Renal Injury with 
Coagulopathy 
 
Independent 
Variable 
Coagulopathy 
No. of Patients 
(%) 
p Value OR (95% CI) 
Renal injury  
Present (7) 4 (57.1 %) 0.19 2.9 (0.53 – 14.58) 
Absent (51) 16 (31.3 %)  1 
 
*p value of less than or equal to0.05 is regarded as significant. **p value of less than 
or equal to0.01 is regarded as highly significant. 
 
Overall 7 patients had acute renal injury. Among these, 4 patients had 
coagulopathy. Similarly, 16 patients without coagulopathy also presented with 
acute renal injury. Thus association of acute renal injury and coagulopathy was not 
statistically significant.( p = 0.19) 
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Table 17 : Multivariate analysis model showing association of Mortality with other 
factors 
 
Independent 
Variable 
Mortality 
No. of Patients 
(%) 
OR (95 % CI) AOR (95% CI) 
Coagulopathy  
Present (20) 5 (40.0 %) 12.3 (1.3 – 114.6) 1.4(0.5- 36.4) 
Absent (38) 1 (2.63 %) 1 1 
Renal injury  
Present (7) 4 (57.1 %) 32.6 (17.7 – 63.5) 3.2 (0.17 – 56.7) 
Absent (51) 2 (3.38 %) 1 1 
Tissue Hypoperfusion (Based on Base Deficit) *  
Present (9) 5 (55.5 %) 7.7(1.25 – 46.95 ) 23.56(8.4 – 117.12) 
Absent (49) 1 (2.04 %) 1 1 
 
 
*p value of less than or equal to0.05 is regarded as significant.  
 
Multivariate analysis is performed to find the association between different variables 
like tissue hypoperfusion, coagulopathy and renal injury with mortality. It proved that 
tissue hypoperfusion is an independent predictor of mortality when compared with 
other variables. 
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Table 18 : Multivariate analysis model of Length of stay with other factors 
 
 
 
*p value of less than or equal to 0.05 is regarded as significant. 
 
Similarly, multivariate analysis is also performed to find the association between 
variables like tissue hypoperfusion and coagulopathy with length of stay in hospital 
(marker of morbidity). It proved that coagulopathy as an independent predictor of 
morbidity). 
 
 
 
 
 
 
 
 
 
Independent 
Variable 
Length of Stay 
>= 11 days 
OR (95 % CI) AOR (95% CI) 
TISSUE HYPOPERFUSION  
Present (4) 3 (75%) 2.3 (0.22 – 24.07) 1.20(0.096 - 15.11) 
Absent (48) 27 (56.5%)           1           1 
COAGULOPATHY *  
Present (15) 12 (80 %) 4.22 (1.02 – 17.46) 4.09(1.93 - 17.88) 
Absent (37) 18 (48.6%) 1 1 
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Table 19 : Multivariate analysis model of Mortality with various parameters of 
coagulation profile 
 *p value of less than or equal to 0.05 is regarded as significant. 
 
Among the individual coagulation parameters like PT, aPTT, D - Dimer, aPTT was 
proved to be an independent predictor of mortality in multivariate logistic regression.  
 
 
 
 
 
 
Independent 
Variable 
Mortality 
No. of Patients 
(%) 
OR (95 % CI) AOR (95% CI) 
Activated Partial tissue Thromboplastin Time   
Abnormal (9) 5(55.5%) 18.8 (2.72 – 129.7) 5.7(1.3 – 52.9) 
Normal (49) 1(2.04%)            1            1 
D – Dimer  
Positive (8) 4(50.0%) 9.4(1.48- 59.59) 23.9(0.45 -85.1) 
Negative (50) 2(4.00%)           1 1 
Prothrombin Time   
Abnormal (20) 5(25.0%) 12.3 ( 1.3 – 114.6) 43.6(0.2 – 96.2) 
Normal (38) 1(2.63%) 1 1 
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DISCUSSION 
Major cause of death and disability worldwide is trauma 
119
, and in this blood 
loss accounts for approximately 40% of all trauma deaths. 
120
  
The prevalence of acute traumatic coagulopathy was found to be 34.5%. This 
prevalence is much lower when compared to the study done by Erick Mujuni et al in 
Uganda population which was 54%.
112
 Other studies reported the prevalence ranging 
from 24 to 34%
 
which is represented in table 20. This could be due to the small 
sample size which includes both minor and major cases of trauma. 
 
Table 20: Prevalence of Coagulopathy mentioned by other studies. 
Study done by No. of Patients 
Prevalence of 
Coagulopathy 
Brohi K et al 2003 
95
 1088 24% 
Macleod at al 2003 
8
 10790 28% 
Meagle et al 2007 
14
 8724 34% 
Brohi.K et al 2007 
6
 208 10% 
 
TYPE OF INJURY 
 Coagulopathy was reported more commonly with blunt injury than penetrating 
injury but it was not statistically significant. This finding was similar to the report 
mentioned in a study done by Erick Mujuni et al in Uganda population.
112
 and in a 
study by Johansson et al.
110
.
 
No other studies reported the relationship between the 
type of injury and occurrence of coagulopathy. 
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SEVERITY OF INJURY  
 As the injury severity increases, the occurrence of coagulopathy also increases 
in our study with p value of 0.027. This was as same as proved by other studies by 
Cosgriff et al and Brohi K et al 
92, 93
 
ACUTE RENAL INJURY  
Acute renal injury occurs generally in hospitalized patients and carries a high 
mortality 
121-123
. The causes are as follows:  
 Pre-Renal 
 Intrarenal and 
 Post-Renal. 124-126  
Pre-renal failure is a reversible increase in serum creatinine and urea due to 
decreased renal perfusion, which in turn leads to decreased GFR 
126
 
When the blood urea concentration is raised, measurement of the serum 
creatinine concentration will definitely differentiate glomerular failure from prerenal 
uraemia.
     127-128
 
Hemorrhage increases the risk of acute renal injury or multiple organ failure 
and late mortality 
120. 
There were 7 patients with acute Renal Injury in total (12.1%) and 4 patients 
(57.1%) had coagulopathy. This was reported as 25.3% in coagulopathy patients and 
8.4 % in patients without coagulopathy in a study by Erick Mujini et al.
112
 and other 
studies by Brohi.K et al.
6  
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TISSUE HYPOPERFUSION 
Base Deficit & Lactate: 
Previous studies have shown that Base deficit cannot be used as a substitute for 
serum lactate. 
129 -130
 Base Deficit had been proven to be impervious for detecting 
elevated lactate. 
131 
Mikulaschek et al proved that decisions regarding resuscitation 
would have been wrong 33-58% of the time if Base deficit had been used as the only 
criterion. 
132
  
Another study reported that the lactate level is a distinct interpreter and may 
not essentially corresponding base deficit.
133
 
Similarly, in this study we did not correlate base deficit and arterial lactate. But 
elevated levels of arterial lactate were significantly associated with mortality with p 
value of 0.001. 
The base deficit is correlated with injury severity and degree of blood loss in 
previous studies. 
46-50  
 In the same way, there was a significant association with 
severity of injury and base deficit of -6 mmol / L. Here it is mentioned as tissue 
hypoperfusion.  
Base deficit of –6 mmol/L was found to be an indicator of severe injury, 
prolonged stay in hospitals, and associated with increased requirement of blood 
transfusion.
134
 The association of tissue hypoperfusion with severity of injury was 
proved to be significant as established by other studies. Tissue hypoperfusion as an 
indicator of increased length of stay was disproved in this study. (no significant 
association between tissue hypoperfusion and length of stay). This can be due to 
correction of hypoperfusion due to blood transfusion than other parameters that 
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determine the outcome. But the correlation of tissue hypoperfusion and transfusion 
requirements is not done as there is no standard protocol adopted for blood 
transfusion. 
 
 
CLINICAL OUTCOME  
Mortality 
 Severe bleeding is one of the chief reasons of mortality 
135
 during first 48 
hours in major trauma. 
136 
The overall Mortality was 6 patients (10 %), This is lower mortality than a 
study conducted by Kirya at Mulago hospital where the mortality was 26%.
137
 
 On the whole, the rate of mortality ranges from 15% to 20% represented in 
Table 21, however these studies were undertaken by trauma care centres with great 
resources. 
 
Table 21 : Percentage of Mortality as reported by other studies. 
Study done by 
No. of Patients 
studied 
Mortality in 
patients with 
Coagulopathy 
Overall 
Mortality 
Brohi K et al 2003 
95
 1088 46% 11% 
Macleod at al 2003 
8
 10790 19% 6% 
Meagle et al 2007
 14
 8724 28% 8% 
Brohi.K et al 2007 
6
 208 62% 8% 
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Patients who arrive in the emergency department with a coagulopathy are three 
to four times more likely to die 
6,8,93,11
 and eight times more likely to die within the 
first 24 hours. 
94 
 The mortality was more in patients with coagulopathy (i.e) 5 patients (40%) 
than in patients without coagulopathy 1 patient (2.6 %) (p value =  0.027). This was 
reported as 29.3 % in coagulopathic and 12.2% in non coagulopathic group in a study 
by Erick mujini et al.
112 
This was also more when compared to other studies
  
mentioned in Table 19,
 
which may be due small sample size. 
 Coagulopathy can be used as an independent predictor of death said by Brohi 
K et al. 
93
 
 This study also proved that tissue hypoperfusion was a good predictor of 
mortality in trauma patients among other parameters like coagulopathy and renal 
injury. This finding disproved the conclusion from a study by Erick Mujini et al 
112. 
Erick Mujini et al concluded that coagulopathy as an independent predictor of 
mortality. The possible explanation could be due to small sample size and very less 
number of patients with tissue hypoperfusion compared to patients with coagulopathy. 
Among tissue hypoperfusion and coagulopathy, coagulopathy was found to be 
a strong predictor of morbidity which was studied using  longer length of stay either 
in ICU or in general ward. This was also reliable with a study by Brohi.K et al 
95
 
Length of stay 
Patients who survived are 52 (90%) in number. They were taken for analysis 
of Length of Stay in hospital. Overall mortality of 10% i.e 6 patients died.  In this 
study there was a significant association between length of stay which was regarded 
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as morbidity parameter and coagulopathy (p value = 0.043). This is consistent with 
other studies 
6, 8, 93, 11
 and similar to Brohi. K et al study report which states that 
Coagulopathy present during admission is associated with prolonged hospital stays.
6
 
 
BLOOD TRANSFUSION 
It is very vital to identify the need of blood transfusion early because it has 
been shown that a postponement in the commencement of coagulation therapy is 
associated with worse clinical outcome.
138 -139
 There is an evidence that the use of high 
plasma : RBC ratios in patients can increase complication rates. 
140 -141 
But here in our study there was no strong association between blood 
transfusion requirements and coagulopathy. A total of 12 patients (60%) with 
coagulopathy were transfused and 5 patients (13.15%) were transfused with blood 
products even in the absence of coagulopathy (p =0.001). This could probably due to 
bleeding at the site of accident and continuous loss secondary to coagulopathy. The 
transfusion requirement for those without coagulopathy may be due failure to follow 
standard protocol for blood transfusion in our hospital setup. 
 
COAGULATION TESTS: 
Routine coagulation tests, such as PT, aPTT are used to assess coagulopathy 
and to guide therapy.
93
 The value of these standard coagulation tests in effectively 
reporting the intricacies of trauma-associated coagulopathy has been challenged.
93, 142- 
143 
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Platelet Count: 
 Canine studies had shown that sequestration of platelets in the liver and spleen 
contributes to bleeding induced by hypothermia.
144-145
 Rewarming quickly reversed 
sequestration. Effects of hypothermia on platelet function was proven by studies 
conducted in other species.
146 -147
 Hypothermia as already explained, very common in 
patients with trauma. 
In trauma, previous clinical studies have demonstrated attenuation of platelet 
stimulation to ADP agonism for patients in hemorrhagic shock, 
148
 and after head 
injury,
149
 with the diminished platelet response to ADP more prominent in patients 
who died  than  patients who survived after life-threatening injury.
150 
Hence abnormal platelet count was significantly associated with mortality 
with p value of 0.028. Out of 9 patients with abnormal platelet count, 3 patients died 
during the follow up period. 
Prothrombin Time : 
 Quick and precise determination of prothrombin time may help in faster control 
of bleeding induced by coagulopathy.
151
 Among 20 patients with abnormal 
prothrombin time, 15 patients survived and 5 patients (25%) died. Thus Prothrombin 
time can be used to assess the coagulation status as well as to predict mortality.(p 
value 0.027)  
Thus from this study, we found that prothrombin time should be done for all 
trauma patients in order to detect early coagulopathy changes. 
aPTT : 
aPTT can be prolonged in the presence of hypothermia. In a study, long-lasting 
acidosis for more than 150 min can result in prolongation of the aPTT and decreases 
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in factor V level. 
152
 As hypothermia and acidosis both are common in patients with 
trauma, aPTT should also be evaluated in trauma.  
Among 20 patients with coagulopathy, 9 patients alone had prolonged aPTT. 
Univariate analysis showed prolonged aPTT is significantly associated with mortality 
with p value of 0.003. This finding was consistent with other studies 
112.  
Macleod et al also reported that reported that the PT and aPTT can be used as 
independent predictors of mortality whereas platelet count cannot be used.
8
 
Fibrinogen level : 
In a recent study, hypotension, increased base deficit and increased degree of 
injury (ISS ≥ 25), were  associated with decreased fibrinogen levels.153 Fibrinogen 
exhaustion is associated with poor outcomes.
154
 This was also proved by in this study 
that decreased fibrinogen level was associated with significant mortality                      
(p value – 0.028) 
 
MARKERS OF FIBRINOLYSIS : 
Fibrinolysis clears thrombi from the vasculature and limits the formation of 
thrombus. Hence enormous activation of coagulation due to injuries may lead to 
unrestrained stimulation of the fibrinolytic system with further creation of 
antithrombin.
155
  
Hypercoagulable state in trauma patients has been proved by many studies 
156 - 
158
 These patients are prone to thromboembolic complications. 
159
 Coagulopathy on 
admission is a risk factor of venous thromboembolism in trauma patients. 
160
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Laboratory evidence has established both decreased fibrinolytic and increased 
fibrinolysis in trauma patients.
161 - 163
 Increased fibrinolytic activity was found 
immediately following trauma and after 24 h in patients with mild to moderate injury 
it returns to normal. In major injuries it remains elevated.
164
 Fibrinolytic activity is 
increased in the presence of hypothermia was also proved by a study.
165
 
Early fibrinolysis was reported in 34% of trauma patients and associated with 
increased blood transfusion requirements, coagulopathy, and bleeding- related 
death.
166
  
Hyperfibrinolysis was associated with increased mortality and appears to be 
related to the injury severity in trauma.
35 
6 patients had positive FDP results in this study. Among those patients, 2 
patients (40%) died. Thus FDP was also significantly associated with mortality          
(p value – 0.046). This was also the same as proved other study done by Fei et al 114 
Fei et al reported that FDP is the best independent indicator of mortality in ICU 
patients. 
  In this study, when fibrinolysis was considered by positive D – dimer levels, 8 
patients (13.8%) had fibrinolysis and 3 patients (3 %) died during the follow up 
period. D- Dimer level was also significantly associated with mortality. (p value 
0.017)  
Thus hyperfibrinolysis was associated with high mortality rates, it can be used 
as a predictor of poor outcome as proved by other studies. 
114
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CONCLUSION 
India is a developing country with a more number of trauma deaths and it is 
one of the leading causes of death. Yet there has not been a major advancement in 
trauma research and coagulation studies in our country.  
The association of coagulopathies with trauma has been well established, yet it 
still faces criticism from various sects of medicine. There is a need for more evidence- 
based studies in this field as the concepts of trauma resuscitation are undergoing 
changes.  
Patients presenting with an established coagulopathy were likely to have poor 
outcomes, and must be identified as soon as possible and treated aggressively. 
Severe injury itself, can lead traumatic coagulopathy which is the major cause 
of failure of hemostasis in these patients. Instantaneous control of blood loss, 
aggressive resuscitation and quick correction of hypothermia improves the survival 
rate of these patients. 
In the quest to improve severe trauma outcomes in an environment with limited 
resources, assessment of coagulation by means of coagulation profile should be done 
routinely. In addition, inexpensive and operational ways to assess or to prevent 
coagulopathy in early stages of trauma should be investigated further. 
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LIMITATIONS 
 Small sample size 
 As the Prothrombin time varies for different laboratories, PT –INR should have 
been considered. 
 In blood transfusion, blood components and number of units transfused was not 
taken into consideration. 
 Core Temperature was not measured as it can indicate hypothermia- an 
aetiology of coagulopathy. 
 Amount of IV fluids administered during resuscitation and during stay in the 
hospital was not taken into account. 
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RECOMMENDATIONS  
 This study can be extended by including a large number of trauma patients 
 Parameters like Protein C, Thrombomodulin, Anti-thrombin can be included to 
study the mechanism of traumatic coagulopathy. 
 Thromboelastography (TEG) can be used instead of routine coagulation tests. 
TEG examines whole blood coagulation and provides information on the rate 
of clot formation. These are key elements in determining the likelihood of 
platelet and clotting factor deficiencies, and fibrinolysis. 
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PROFORMA 
1. Name of the Patient               :         IP.No : 
2. Age       : 
3. Sex       : 
4. Occupation      : 
5. Educational status     : 
6. Date and Time of Admission   :     
7. Present Illness     : 
8. History of Present illness     : 
 Time  & Date of Accident  : 
 Cause of Injury   : 
 Type of Injury   : 
 H/o  first aid    :    
 Drugs given during first aid :    IV fluids / Blood 
transfusion  
9. Past Medical History    : 
 H/s/o Diabetes Mellitus  : Yes / No 
 H/s/o Hypertension   : Yes / No 
 H/s/o Chronic Renal Failure : Yes / No 
 H/s/o Liver Disease   : Yes / No 
 H/s/o Heart disease   : Yes / No 
10. Past Surgical History 
 H/o valve replacement surgeries    
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11. Drug History       
12. Menstrual History 
EXAMINATION 
 General Examination 
 Pallor / Icterus / Pedal edema    
 Vital signs  
 Temperature   - 
 Pulse rate   - 
 Blood Pressure  - 
 Respiratory Rate  - 
 Systemic Examination  
 CVS     - 
 RS    - 
 Abdomen   - 
 CNS ( GCS Scoring) -  
 Grading of Injury 
Revised Trauma Score - 
 Length of stay 
 Blood transfusion given or not 
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PARAMETERS 
 S.No PARAMETERS DAY 0 DAY 2 DAY 6 DAY 14 
1. Temperature     
2. Pulse Rate     
3. Respiratory Rate     
4. Blood Pressure     
5. Blood Urea (mg/dl)     
6. Serum Creatinine (mg/dl)     
7. Bleeding Time ( mins)     
8. Clotting Time ( mins)     
9. Platelet count ( lakhs / cu.mm)     
10. Prothrombin Time ( sec)     
11. 
Activated Tissue Thromboplastin 
Time (sec) 
    
12. Fibrinogen (mg/ dl)      
13. 
Fibrinogen Degradation Product         
( + / -) 
    
14. D – Dimer ( + / -)     
15. Base Deficit ( ABG Report)     
16. Serum Lactate     
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CONSENT FORM 
(To be obtained from subject) 
You are requested to participate in a study conducted in department of Physiology  
titled  “Pattern of Coagulation profile in patients with Trauma” 
Your participation in this study is voluntary. You act at liberty to participate withdraw 
from the study. Please read this consent form carefully and ask the Consultant, any 
questions you may have about the study before signing. 
EXPLANATION OF PROCEDURES:  
If you agree to participate in this study, we will ask some questions to you and 
collect relevant information you may be examined by the investigator if found  to have 
illness. Data from the study will be used for research purpose only. The results of the 
study will not be given to you directly. There will be no cost to you for participating in 
this study. The venous blood sample 3 ml will be  screened for parameters like 
Bleeding Time (BT), Clotting Time (CT), Prothrombin Time (PT), activated Partial 
Tissue Thromboplastin Time (aPTT), Platelet counts, Fibrinogen, Fibrinogen 
Degradation Product, D-dimer, Blood Urea, Serum Creatinine and Serum Lactate. 2ml 
of arterial blood will be taken for Arterial Blood Gas (ABG) analysis  
 
POTENTIAL BENEFITS: 
Your participation will help us to study the incidence and probable cause of 
this problem and  the results of this study will be beneficial for future generations. 
ASSURANCE OF CONFIDENTIALITY:  
The information concerning your participation in the study will be kept 
confidential to the full extent permitted by law and used only for scientific purpose. 
No one except members of the research team will have access to the results. Your 
name will not be disclosed in any report or released in any way.  
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PATIENT CONSENT: 
 I have read the explanation about this study and have been given the 
opportunity to discuss it and to ask questions. I have not received money from 
participants in this study.  
 
Signature of Subject        Signature of Witness  
Date:                      
 Signature of Researcher 
            
        
   (Dr.B.AANANTHA LAKSHMI) 
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REVISED TRAUMA SCORE CALCULATION 
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